Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: ARA-290
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Erythropoietin-derived peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Designed innate-repair-receptor activity without assuming erythropoietic equivalence.
Evidence and critical reading
Reported scientific and empirical uses
Recovery and connective tissue
The guide distinguishes sarcoidosis-associated neuropathy, other diagnoses and empirical uses. The handbook describes a subcutaneous regimen; the selected trial used an intravenous regimen.
Human evidence
A 22-person sarcoidosis-neuropathy pilot showed selected symptom signals; exploratory and small.
Preclinical evidence
Cytoprotection/allodynia models motivate research, not broad neural regeneration claims.
Critical reading and limitations
The 22-participant study found a symptom-scale signal, while BPI pain and fatigue improved similarly in both groups. It does not establish anatomical repair, route equivalence or long-term safety.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
2 mg · Amount per administration
- Frequency
- 3 times weekly
- Duration
- 4 weeks
- Route
- Intravenous
- Context
- Exploratory randomized trial in 22 patients with sarcoidosis and small-fiber neuropathy.
- Presentation
- Interpretation
- One neuropathic symptom score improved; BPI pain and fatigue improved similarly in both groups. Small short study, not a general-use regimen.
PMID23168581 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
4 mg · Amount per administration
- Frequency
- 3–5 times weekly
- Duration
- 4–5 weeks
- Route
- Subcutaneous
- Context
- Neuropathy including sarcoidosis as described by the handbook; not a verified regulatory indication.
- Presentation
- Concentration: 6 mg/mL · Container volume: 4 mL
- Interpretation
- Regimen attributed to the handbook; correspondence to a specific primary trial remains pending. Distinct from the intravenous trial described separately.
manual01 · Page 26 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
No safety concern detected in the small pilot does not exclude rare or long-term harms; interactions unresolved.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID23168581 · Exploratory randomized double-blind trial
Sarcoidosis with small-fiber neuropathy.
Intravenous, four weeks.
Neuropathy-scale signal; BPI and fatigue improved similarly between groups.
Small and short; does not show anatomical regeneration or SC equivalence.
n = 22
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Cibinetide · 4 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06626971 · The Use of ARA290 for the Treatment of Diabetic Macular OedemaRegistry status: TerminatedLast update posted: October 4, 2024Query verification: October 16, 2026
NCT02039687 · Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisRegistry status: CompletedLast update posted: April 18, 2017Query verification: October 16, 2026
NCT01933529 · ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)Registry status: UnknownLast update posted: September 3, 2015Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID23168581
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A.
October 16, 2026
- R36
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026